BIIB NASDAQ
Biogen Inc.
1W: +8.0%
1M: +10.8%
3M: +22.7%
YTD: +41.9%
1Y: +68.1%
3Y: -2.0%
5Y: -6.5%
$252.73
+0.47 (+0.19%)
After Hours: $252.04 (-0.69, -0.27%)
Weekly Expected Move ±4.4%
$229
$240
$251
$262
$273
Credit Risk of going bust: lower than 68% of companies Debt: 18.3% of company value Bonds: $137.0M held by 192 funds, 91 bp over Treasuries → details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.22 (down 98%), Biogen Inc. would be worth roughly what it owes.
Total debt $8.36B against a stock market value of $37.27B.
Distance to default 7.34 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.45B (short-term plus half of long-term), stock volatility 33.9%; Altman Z 3.16. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $4.22 (down 98%), Biogen Inc. would be worth roughly what it owes.
Total debt $8.36B against a stock market value of $37.27B.
Distance to default 7.34 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $4.45B (short-term plus half of long-term), stock volatility 33.9%; Altman Z 3.16. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.45
Bullish
1 bullish
1 neutral
0 bearish
Articles (24h)
2
Hourly Sentiment (24h)
0.40
Bullish
4 bullish
5 neutral
0 bearish
Articles (7d)
9
Daily Sentiment (7 Days)
Articles (100)
Biogen Q3 2026 Earnings Preview
Apollon Wealth Management LLC Buys 40,607 Shares of Biogen Inc. $BIIB
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus
Earnings Week Ahead: MSFT, GOOGL, AMZN, XOM, BA, VZ, and more
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking Therapeutics
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now
Biogen Inc. $BIIB Shares Acquired by CWA Asset Management Group LLC
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results
Biggest stock movers Monday: CCC, BIIB, and more
Biogen upgraded at JPMorgan with $300 PT on 2027 pipeline catalysts, shares rise
Pharma lobby group sues Trump administration over MFN pricing
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
Biogen phase 2 litifilimab data boosts lupus candidate
Design Therapeutics a new overweight at Wells Fargo on Friedreich ataxia program
Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
Nykredit A S Makes New $8.02 Million Investment in Biogen Inc. $BIIB
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
Trump administration is said to weigh allowing most pharma licensing deals with China
Looming biosimilar void risks $189B in lost U.S. healthcare savings: report
Roche succeeds in late-stage study for Lunsumio regimen in follicular lymphoma
Corient Private Wealth LP Raises Stock Holdings in Biogen Inc. $BIIB
Baird Financial Group Inc. Increases Stock Holdings in Biogen Inc. $BIIB
How AbbVie's Neuroscience Portfolio Has Transformed Over the Years
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
S&P 500 gainers: Today’s top performers ranked by Quant
FDA names acting heads of drug and vaccine units to permanent roles
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China
Novartis and Alteogen ink injectable drug delivery deal worth up to $3.2B
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease
Canada Pension Plan Investment Board Makes New Investment in Biogen Inc. $BIIB
Why Is Biogen (BIIB) Up 6.5% Since Last Earnings Report?
FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now
Bank of Nova Scotia Buys Shares of 16,446 Biogen Inc. $BIIB
Allworth Financial LP Takes $1.74 Million Position in Biogen Inc. $BIIB
Should You Buy, Sell or Hold Biogen Stock After a 9% Rise in a Month?
Trump nominates White House adviser Overton as next FDA commissioner
15,985,736 Shares in Biogen Inc. $BIIB Bought by BlackRock Inc.
Trump expected to nominate White House aide Heidi Overton as FDA commissioner
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum
Biogen Completes Acquisition of RayThera Inc.
Biogen Completes Acquisition of RayThera Inc.
Why Supernus Pharmaceuticals Stock Topped the Market Today
Biogen Inc. $BIIB Shares Acquired by Amundi
IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook
Why Biogen Stock Topped the Market Today
Q2 Earnings Season in Full Swing
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised
Investors Await Fed Decision Today
Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates
Here are the major earnings before the open Wednesday
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Earnings week ahead: AAPL. MSFT, AMZN, META, XOM, PYPL, CVX, F, KO, ABBV, V, QCOM, BA, MO, SOFI, and more
Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?
Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
Biogen Inc. $BIIB Shares Purchased by California Public Employees Retirement System
AIA Group Ltd Raises Stake in Biogen Inc. $BIIB
Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Roche/ Biogen kidney drug granted FDA priority review for label expansion
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
Biogen Wins FDA Approval for Subcutaneous Starter Dose of Leqembi
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Biogen nabs approval of subcutaneous version of Leqembi for initiation dose
Stock Market Today, July 13: Energy Stocks Cushion Dow as Tech Slides on Geopolitical Tensions
Notable healthcare headlines for the week: UnitedHealth, Vertex, and CVS Health in focus
2 Fast-Growing Pharmaceutical Stocks to Buy Now
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
Stock futures slide as doubts rise over U.S.-Iran ceasefire
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study
Why Biogen (BIIB) is Poised to Beat Earnings Estimates Again
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
Amgen or Biogen: Which Biotech Stock Appears Better Poised?
New Strong Sell Stocks for June 30th
Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms
Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump?
FDA Expands IONS' Tryngolza Label to Treat Severe Hypertriglyceridemia
Biotech breakout: iShares Biotechnology ETF hits all-time high
Denali to Sell Priority Review Voucher for $195M Cash Boost
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday